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Abstract
Breast cancer is one of the most prevalent forms of cancer among American women. Vitamin D
has been shown to reduce the risk of developing breast cancer, in part by preventing the formation of new
blood vessels (termed angiogenesis) within tumors. Vascular Endothelial Growth Factor (VEGF), a
potent angiogenic factor, has been shown to be regulated by the active form of vitamin D, 1,25dihydroxyvitamin D (1,25(OH)2D). It has been proposed that 1,25(OH)2D does not directly decrease the
expression of VEGF, but rather acts indirectly through Hypoxia Inducible Factor-1α (HIF-1α), a direct
transcriptional regulator of VEGF. 1,25(OH)2D may impact HIF-1α in one of two ways: gene
transcription or stability of the protein, which is degraded through the actions of Prolyl Hydroxylase
(PHD). The purpose of this study was to determine the impact of 1,25(OH)2D on VEGF, HIF-1α, and
PHD mRNA expression in MCF10A breast epithelial cells which are untransformed (LXSN) or which
contain the ErbB2 oncogene. ErbB2 is an oncogene that is commonly overexpressed and associated with
an increased aggressiveness in breast cancer. The MCF10A are a model of multistage carcinogenesis,
models that are important to use when studying cancer prevention. The hypothesis of this study is that
1,25(OH)2D decreases the gene expression of VEGF and HIF-1α, and increases the gene expression of
PHD in untransformed breast epithelial cells and breast epithelial cells transfected with ErbB2.
Treatment of LXSN cells with increasing concentrations of 1,25(OH)2D (1 nM, 10 nM, and 100 nM) for
24 hours resulted in increasing concentrations of VEGF mRNA and decreasing concentration of PHD
mRNA levels compared to the vehicle control. However, these differences were not significant (p>0.05)
except at a high dose of 1,25(OH)2D (100 nM). Increasing doses of 1,25(OH)2D did not significantly
alter HIF-1α mRNA abundance (p>0.05) compared to the vehicle control. Treatment of the ErbB2containing cells with the same increasing concentrations of 1,25(OH)2D showed no significant difference
in the concentration of VEGF or HIF-1α mRNA (p>0.05) compared to the vehicle control. The PHD
mRNA expression decreased with increasing concentrations of 1,25(OH)2D, however this was only
significant (p>0.05) at the high dose of 1,25(OH)2D (100 nM). These results suggest that in
untransformed MCF10A breast epithelial cells, 1,25(OH)2D increases the expression of VEGF mRNA at
high doses, but not through an increased expression of HIF-1α mRNA. In the MCF10A breast epithelial
cells transfected with ErbB2, 1,25(OH)2D had no significant impact on the expression of VEGF or HIF1α mRNA.

Purpose
The purpose of this study was to determine the impact of 1,25(OH)2D on VEGF, HIF-1α, and
PHD mRNA expression in untransformed MCF10A (LXSN) and oncogene (ErbB2) transfected MCF10A
breast epithelial cells
Literature & Rationale
Breast cancer is a form of cancer that is quite prevalent among American women. The CDC
reports that 186,467 women were diagnosed with breast cancer and 41,116 died from the disease in
2005(16). Breast cancer, like all forms of cancer, progresses through a series of steps that is termed
multi-stage carcinogenesis (15). Tumor development, or carcinogenesis, can be divided into 4 steps:
tumor initiation, tumor promotion, malignant conversion, and tumor progression (13). Tumor initiation is
the result of the accumulation of irreversible genetic damage and is commonly the result of the activation
of an oncogene. An oncogene is a normally functioning gene in a cell that has been altered by mutation
and acts to contribute to the growth of a tumor (4). The next step in carcinogenesis is an accumulation of
initiated cells and is termed tumor promotion. Once there are a large number of initiated cells, they
become susceptible to a malignant conversion. This means that the initiated cells are altered to express a
malignant phenotype, which usually causes the uncontrolled growth that is the hallmark characteristic of
cancer cells. The dominant step of carcinogenesis is tumor progression. This is the step where the cell
displays uncontrollable growth and the development of tumors. Metastasis is also observed in this stage
of cancer development. Metastasis is the process of the spreading of cancer from its initial site to other
areas of the body (3). Breast cancer is particularly fatal because of the increased likelihood of metastasis
(9). One gene that is an important regulator of metastatic potential and is responsible for the rapid growth
found in the mammary epithelium tissues that is associated with the presence of this form of cancer is the
ErbB2 oncogene (14,9). An over expression of this oncogene is found in approximately 30% of breast
cancer patients (9).
The rapid, uncontrollable growth of tumor cells requires in part, an increase in angiogenesis.
Angiogenesis is the process of developing new blood vessels and is a major determinant in the growth of
a tumor (12). In order for tumor cells to grow and thrive, they must have a ready supply of oxygen and
nutrients, which are supplied by the bloodstream. The development of new blood vessels to tumor cells is
critical for the growth of the tumor. The process of angiogenesis has four stages: (1) degrading the
basement membrane of existing vasculature, (2) proliferation and migration of endothelial cells, (4)
attachment of preexisting endothelial cells to new channels, and (10) formation of new basement
membrane and maturation of the new vasculature (12).

In addition to the other effects of ErbB2, the protein product of this oncogene is linked to an
increased production of Vascular Endothelial Growth Factor (VEGF), a potent stimulator of angiogenesis
(10). The action of VEGF is primarily targeted towards the endothelial cell of the vasculature. VEGF
acts by binding to a receptor (VEGFR2) and activating a signaling cascade. This cascade then acts to
increase the permeability, proliferation, and migration of vascular endothelial cells (6). Since the
proliferation and migration of vascular endothelial cells are major events in angiogenesis, a compound
with the ability to inhibit the production of VEGF may hinder the rapid growth of tumors and prevent the
development of metastatic cancers.
Recently, the link between vitamin D and a decreased risk of cancer has received much attention
(1). Vitamin D is available in two main forms: in the diet or from a biological conversion that occurs in
the skin. Dietary sources of vitamin D include natural and fortified foods. The most typical source of
natural vitamin D is the fatty fish, such as salmon. Some of the fortified sources of vitamin D include:
milk, orange juice and some cereals (7). The vitamin D that is produced in reaction to the absorption of
sunlight represents the major source of vitamin D in most people. When sunlight is absorbed by the 7dehydrocholesterol in an individual’s skin, it is converted to previtamin D3. Previtamin D3 is quickly
converted into a biologically significant isomer, vitamin D3. Vitamin D3 is then released into the
bloodstream where it binds to the vitamin D-binding protein (7).
Once the vitaminD3 that is produced in the skin and the vitamin D that is consumed in the diet are
present in the bloodstream they are taken up by the liver where they are metabolized to 25hydroxyvitamin D [25OHD]. The vitamin D metabolite 25OHD is the circulating form of vitamin D that
is used to assess an individual’s vitamin D status. However, this is not the biologically active form of
vitamin D and another hydroxylation is required to produce the biologically active form 1,25dihydroxyvitaminD [1,25(OH)2D] (10). 25(OH)D was traditionally thought to be converted to
1,25(OH)2D via the kidneys and functioned to regulate serum calcium levels, blood pressure, and insulin
secretion (7). However, it was discovered that extrarenal tissues, such as colon, prostrate, breast, and
immune cells, also express the enzyme 25-hydroxyvitamin D-1α-hydroxylase (1-OHase) which is
necessary in the conversion of 25(OH)D to 1,25(OH)2D. 1, 25(OH)2D which is produced in these
extrarenal cells may act to inhibit cell proliferation and cell differentiation and act to induce apoptosis (5).
It is this ability of 1,25(OH)2D in specific tissues to arrest cell growth and differentiation that is drawing
much attention in the role of cancer prevention.

There have been several studies performed testing the link between vitamin D and cancer. In
1941, epidemiological evidence was used to support an observation that individuals living in northern
states in the United States were more likely to die of cancer than individuals living in the southern states
(5). This led others to consider the link between sunlight exposure, vitamin D status, and cancer risk.
John, et al., analyzed data from The National Health and Nutrition Examination Survey (NHANES) I
Epidemiologic Follow-up Study to look at the potential protective role of vitamin D in breast cancer risk
(8). They looked at the relationship of sunlight exposure and dietary intake of vitamin D to the
development of breast cancer. They found that women who lived in areas with adequate sunlight
exposure and dietary intake of vitamin D were associated with a 25-65% reduction in breast cancer risk.
It can be inferred from this data that adequate intake of vitamin D and a corresponding adequate vitamin
D status provides breast cells with adequate substrate [25OHD] for conversion into the active form
1,25(OH)2D, which in turn may act to inhibit tumor progression.
Another study that was conducted to study the link between vitamin D status and tumor
progression was performed by Tangpricha et al (8). Tangpricha et al. studied the progression of a cancer
cell line in mice that were vitamin D deficient or vitamin D sufficient. They placed the cancer cells in the
two mouse treatment groups and observed the growth of the tumor. The mice that were vitamin D
deficient had tumors that grew much more rapidly than the tumors in the vitamin D sufficient mice. This
observation suggests that vitamin D status is an important factor in the reduction of tumor growth and
slowing cancer progression.
In 2002, one study looked at the local production of 1,25(OH)2D and its role in inhibiting cancer
growth (5). They studied a prostate cancer cell line which either had 1-OHase or lacked 1-OHase
activity. It was found that the cells without 1-OHase were not able to use 25OHD but if they were treated
with 1,25(OH)2D there was a marked decrease in cellular growth. The cells that had active 1-OHase
present also displayed a marked decrease in cellular growth. This data also supports the theory that
increased concentrations of 1,25(OH)2D in cancer cells is related to an inhibition of cellular growth.
The exact mechanism of the role of vitamin D in the inhibition of cancer progression is not
known. However, a main role for vitamin D in cancer prevention appears to be the inhibition of
angiogenesis (1). Since VEGF is such a potent stimulator of angiogenesis, the link between the
regulation of VEGF by 1,25(OH)2D and the progression of cancer is vital. It is proposed that the action
of the active vitamin D metabolite 1,25(OH)2D acts to decrease the expression of VEGF (1) in two ways:
by decreasing the expression of HIF-1α mRNA or increasing the expression of Prolyl Hydroxylase (PHD)
mRNA(Figure 1).

Figure 1 - Impact of increased concentrations of 1,25(OH)2D in cell models

The active vitamin D compound, 1,25(OH)2D has been shown to decrease the concentration of
Hypoxia Induced Factor1α (HIF-1α) mRNA. This was shown by Ben-Shoshan et al, who demonstrated
that treating prostate and colon cancer cells with increasing concentrations of 1,25(OH)2D reduced the
levels of HIF-1α protein produced in a dose-dependent manner. They also demonstrated in this study that
this regulation of HIF-1α occurs during translation, decreasing the concentration of HIF-1α mRNA.
While HIF-1α does not directly influence the process of angiogenesis, it has a role in activating
angiogenic stimulators such as VEGF. HIF-1α heterodimerizes with HIF-1β to form the HIF-1transcription factor (10). This compound stimulates angiogenesis by binding to the promoter region of
the VEGF gene and up-regulating VEGF mRNA expression (10). This increase in VEGF mRNA
expression leads to an increase in VEGF protein and a corresponding increase in angiogenesis.
The other action of 1,25(OH)2D may be to increase the expression of PHD mRNA. Increasing
the expression of PHD mRNA leads to a corresponding increase in concentration of the PHD protein,
which results in an increased degradation of the HIF-1α protein (2). PHD contributes to the regulation of
HIF-1α by binding to HIF-1α under normoxia conditions. The resulting complex is targeted for
degradation via a complex ubiquitin-proteasome pathway (8). Although there is evidence that
1,25(OH)2D both up and down-regulates the VEGF protein, dependent on the status of the cell(1), the
mechanism by which 1,25(OH)2D mediates these changes has not been explored. This study sought to try
and close this gap in the knowledge of the how vitamin D acts to inhibit the progression of cancer.

Study Design & Methods
Cell Type
The MCF10A human epithelial breast cells were used in this experiment. The MCF10A cells are
derived from normal, untransformed tissues and maintained in Mammary Epithelial Growth Medium
(MEGM). The two cell models used include: MCF10A which expresses the ErbB2 oncogene and the
untransformed MCF10A cell containing LXSN, the empty plasmid for the ErbB2 oncogene.
Cell Treatments
The LXSN and the ErbB2 cell models were plated in 6-well-plates and treated with varying
concentrations of 1,25(OH)2D. The four experimental groups included: an ethanol vehicle, 1 nM
1,25(OH)2D, 10 nM 1,25(OH)2D, and 100 nM 1,25(OH)2D. The cells were harvested 24 hours following
the treatment.
Methods
After harvest, total RNA was extracted and quantified. Extraction of the RNA allowed the
expression of HIF-1α, VEGF, and PHD mRNA to be assessed with real time polymerase chain reaction
(PCR). Primers for HIF-1α, VEGF, and PHD have been designed and optimized for the MCF10A cell
line.
Human VEGF primer:

CAAGATCCGCAGACGTGTAA
TCACATCTGCAAGTACGTTCG

Human HIF-1 primer:

TGCTGAAGACACAGAAGCAAA
AAAGCGCAAGTCCTCAAAGC

Human GAPDH primer:

TCACCATCTTCCAGGAGCG
CTGCTTCACCACCTTCTTGA

Prolyl Hydroxylase primer:

CTTTGACCGGTTGCTCATTT
TAGGCGGCTGTGATACAGGT

The controls included no temperate controls and no RT, to ensure the lack of genomic DNA
contamination. The SYBR green system was used for visualization. The normalization gene was 18S
and data is expressed as ΔΔ Ct method for determination of fold change over control samples. Standards
were composed of aliquots of PCR products in 10-fold serial dilutions ranging from 109 to 101 molecules.
Standards were amplified in triplicate and used to calculate a regression of threshold cycle on the
molecule copy number to determine a log value of starting abundance for each cDNA aliquot, amplified
in duplicate, based on individual threshold cycle. The abundance of mRNA was analyzed, quantified, and
statistically evaluated.

Statistical Analysis
The statistical significance was assessed by an analysis of variance (ANOVA). A statistical
significance is defined as p<0.05. A trend towards statistical significance is defined as being between
0.005-0.100.
Results
Impact of 1,25(OH)2D on VEGF mRNA expression in Untransformed Breast Epithelial Cells
In the untransformed breast epithelial cells, the LXSN cell line, increasing concentrations (1 nM,
10 nM, 100 nM) of 1,25(OH)2D did not significantly impact the expression of VEGF mRNA at a
physiological of 10 nM(Figure 2). However, at the higher concentration (100 nM) an increase was
observed, although this increase was not significant (p>0.05). There was also a decrease observed at the
low concentration (1 nM) which had a p-value with a trend toward significant (0.05 < p < 0.10).
Impact of 1,25(OH)2D on HIF-1α mRNA expression in Untransformed Breast Epithelial Cells
In the untransformed breast epithelial cells, the LXSN cell line, increasing concentrations (1 nM,
10 nM, 100 nM) of 1,25(OH)2D did not significantly impact the expression of HIF-1α mRNA within a
physiological range of 10 nM or less (Figure 3). However, at the higher concentration (100 nM) an
increase was observed, but was not significant (p>0.05). There was a significant difference (p > 0.05)
between the 1 nM and 100 nM treatments, but not between either of these treatments and the vehicle.

Impact of 1,25(OH)2D on PHD mRNA expression in Untransformed Breast Epithelial Cells
In the untransformed breast epithelial cells, the LXSN cell line, increasing concentrations (1 nM,
10 nM, 100 nM) of 1,25(OH)2D did not significantly impact the expression of PHD mRNA at a
physiological level of 10 nM (Figure 4). However, at high concentrations (100 nM) there was a decrease
in the amount of PHD mRNA, although this decrease was not significant (p > 0.05). There was a
significant difference (p > 0.05) between the 1 nM and 100 nM treatments, but not between either of these
treatments and the vehicle.
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Figure 2 - The Regulation of VEGF mRNA Expression by 1,25(OH)2D. Untransformed (LXSN) cells were treated with
vehicle or increasing concentrations of 1,25(OH)2D, and following harvest the expression of VEGF mRNA assessed by
PCR. Bars with different letters are significantly different (p-value < 0.05) as assessed by ANOVA.
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Figure 3 – The Regulation of HIF-1α mRNA Expression by 1,25(OH)2D. Untransformed (LXSN) cells were treated with
vehicle or increasing concentrations of 1,25(OH)2D, and following harvest the expression of VEGF mRNA assessed by
PCR. Bars with different letters are significantly different (p-value < 0.05) as assessed by ANOVA.
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Figure 4 – The Regulation of PHD mRNA Expression by 1,25(OH)2D. Untransformed (LXSN) cells were treated with
vehicle or increasing concentrations of 1,25(OH)2D, and following harvest the expression of VEGF mRNA assessed by
PCR. Bars with different letters are significantly different (p-value < 0.05) as assessed by ANOVA.

Impact of 1,25(OH)2D on VEGF mRNA expression in Breast Epithelial Cells Transfected with ErbB2
In the breast epithelial cells transfected with the ErbB2 oncogene, increasing concentrations
(1 nM, 10 nM, 100 nM) of 1,25(OH)2D did not significantly impact the expression of VEGF mRNA
(Figure 5).
Impact of 1,25(OH)2D on HIF-1α mRNA expression in Breast Epithelial Cells Transfected with ErbB2
In the breast epithelial cells transfected with the ErbB2 oncogene, increasing concentrations
(1 nM, 10 nM, 100 nM) of 1,25(OH)2D did not significantly impact the expression of HIF-1α mRNA
(Figure 6).
Impact of 1,25(OH)2D on PHD mRNA expression in Breast Epithelial Cells Transfected with ErbB2
In the breast epithelial cells transfected with the ErbB2 oncogene, increasing concentrations (1
nM, 10 nM, 100 nM) of 1,25(OH)2D did not significantly impact the expression of PHD mRNA at
physiological level of 10 nM (Figure 7). However, at high concentrations (100 nM), 1,25(OH)2D acted
to decrease the expression of PHD mRNA.
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Figure 5 – The Regulation of VEGF mRNA Expression by 1,25(OH)2D. Epithelial cells transfected with the ErbB2
oncogene were treated with vehicle or increasing concentrations of 1,25(OH)2D, and following harvest the expression of
VEGF mRNA assessed by PCR. Bars with different letters are significantly different (p-value < 0.05) as assessed by
ANOVA.
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Figure 6 – The Regulation of HIF-1α mRNA Expression by 1,25(OH)2D. Epithelial cells transfected with the ErbB2
oncogene were treated with vehicle or increasing concentrations of 1,25(OH)2D, and following harvest the expression of
VEGF mRNA assessed by PCR. Bars with different letters are significantly different (p-value < 0.05) as assessed by
ANOVA.
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Figure 7 - The Regulation of PHD mRNA Expression by 1,25(OH)2D. Epithelial cells transfected with the ErbB2
oncogene were treated with vehicle or increasing concentrations of 1,25(OH)2D, and following harvest the expression of
VEGF mRNA assessed by PCR. Bars with different letters are significantly different (p-value < 0.05) as assessed by
ANOVA.

Discussion
In this study we treated two cell lines, untransformed breast epithelial cells and breast epithelial
cells transfected with the ErbB2 oncogene, with varying concentrations (1 nM, 10 nM, & 100 nM) of
1,25(OH)2D for 24 hours. We then isolated and quantified the RNA from these cells and performed a
PCR test to determine the amount of mRNA that was present in the cells. We looked at the amount of
VEGF, HIF-1α, and PHD present in these cells.
There were two main questions that were considered with this study. First, was to determine
what the effect of 1,25(OH)2D was on the gene expression of VEGF, HIF-1α, and PHD in untransformed
breast epithelial. Upon statistical analysis of the data, we observed trends. With respect to VEGF, it
appeared that as the concentration of 1,25(OH)2D increased, the concentration of VEGF mRNA increased
in the untransformed cells, although the results were not statistically significant (Figure2). The
expression of HIF-1α mRNA did change with increasing concentrations of 1,25(OH)2D , except at a high
concentration of 100 nM, although this increase was not significant (Figure 3). The PHD mRNA
decreased, though not significantly, with increasing concentrations of 1,25(OH)2D (Figure 4). We
expected that the VEGF and HIF-1α mRNA would increase together since HIF-1α is a regulator of
VEGF. However, this might be explained by alterations in protein level. In our laboratory, other students
determined the effect of treatment of untransformed cells and cells transfected with the ErbB2 oncogene

with the same varying concentrations of 1,25(OH)2D (1 nM, 10 nM, 100 nM) on protein expression of
HIF-1α. They showed that in the untransformed cells, increasing concentrations of 1,25(OH)2D
corresponded with an increasing expression of HIF-1α protein. This suggests that VEGF might be
regulated by HIF-1α at a protein level rather than at a transcriptional level. This hypothesis is supported
by the decrease in PHD mRNA expression. With less PHD being expressed, there might be less PHD
protein to degrade the HIF-1α protein and more available HIF-1α protein available to alter VEGF
transcription.
The other main question that was considered in this study was the effect of the ErbB2 oncogene
on the 1,25(OH)2D-induced gene expression of VEGF. The VEGF mRNA expression in the ErbB2 cells
appeared to decrease with increasing concentrations of 1,25(OH)2D (Figure 5). However, this trend was
not significant (p > 0.05). There did not appear to be a significant difference in the gene expression of
HIF-1α in the ErbB2 transfected cells (Figure 6). The expression of PHD was not significantly different
except at high concentrations (100 nM) of 1,25(OH)2D (Figure 7). The protein expression of HIF-1α
determined in our laboratory indicated that protein expression of HIF-1α in ErbB2 cells was not
significantly different from the vehicle. While the trends in VEGF expression are not significant, they are
similar to the decreases in VEGF mRNA expression with treatment of 1,25(OH)2D that are found in the
literature (1). It may be that with a larger sample size and subsequent reduction in error, a statistically
significant result would be achieved.
Conclusion
In untransformed MCF10A breast epithelial cells, 1,25(OH)2D increases the expression of VEGF
mRNA but not through an increased expression of HIF-1α. We also observed that in MCF10A breast
epithelial cells transfected with the ErbB2 oncogene 1,25(OH)2D did not significantly impact the
expression of VEGF or HIF-1 α expression.
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